Compare Guardant Health Inc. Common Stock (GH) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Guardant Health Inc. Common Stock vs Illumina, Inc. — how do they compare? Guardant Health Inc. Common Stock trades at $168.88 (market cap $22.22B), while Illumina, Inc. trades at $269.18 (market cap $39.95B). The key difference: Illumina, Inc. is the larger of the two by market cap, and Illumina, Inc. is more actively traded (3,169,503 versus 1,589,453). Which is the better fit depends on your goals — on Pluang, investors hold Guardant Health Inc. Common Stock for 0 Days and Illumina, Inc. for 83 Days on average.
| GH | ILMN | |
|---|---|---|
Market Cap | $22.22B | $39.95B |
Volume | 1,589,453 | 3,169,503 |
Sector | Health | Health |
52-Week High | $187.22 | $293.69 |
52-Week Low | $61.73 | $91.00 |
Typical Hold Time | 0 Days | 83 Days |
Enterprise Value | $22.86B | $41.31B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Illumina (ILMN) trades at $267.76, down 2.11% today but remains near recent highs after a strong 94.9% YTD rally. The stock shows bullish technical momentum with recent earnings beats and improved profitability, with net income turning positive to $850 million in 2025 after previous losses. S&P 500 inclusion in September 2026 and growing AI integration in genomics provide positive catalysts, though valuation metrics remain elevated with a P/E of 49.36.
Outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI adoption, while risks include China headwinds, margin pressure, and high valuation multiples requiring sustained execution to justify premium pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Guardant Health Inc. Common Stock
Guardant Health develops blood tests for cancer care. Its tests support genomic profiling, cancer screening, recurrence monitoring, and treatment decisions.
Read more on GH →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
